Health-care companies slid after a profit warning from Eli Lilly. Shares of the obesity ... Rival weight-loss and diabetes drug maker Novo Nordisk fell in sympathy. Pfizer shares fell after ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

There is some expectation that Eli Lilly's pipeline will break through, and analysts are particularly optimistic about diabetes and oncology treatments. Factors including these recent strong ...

Obesity is a growing concern in India, contributing to conditions such as type-2 diabetes and cardiovascular ... BT: Are there other drugs in Eli Lilly’s pipeline targeting obesity or related ...